Guggenheim Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. (NYSE:MRK) had its price objective lifted by Guggenheim from $145.00 to $146.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price objective indicates a potential upside of 13.81% from the stock’s previous close.

MRK has been the topic of a number of other reports. Weiss Ratings downgraded shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Wells Fargo & Company raised their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, July 8th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. Thirteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $134.56.

Merck & Co., Inc. Price Performance

MRK opened at $128.28 on Wednesday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock has a market capitalization of $316.83 billion, a P/E ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. The company’s 50 day simple moving average is $123.45 and its 200-day simple moving average is $118.78. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Institutional Trading of Merck & Co., Inc.

Hedge funds and other institutional investors have recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after buying an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC lifted its position in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after buying an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC boosted its stake in shares of Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after buying an additional 6,897 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after buying an additional 359,356 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above analysts’ $16.37 billion estimate and up 5.1% year over year. Adjusted EPS was a loss of $0.13, but this was better than the expected loss of $0.26. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda and newer products drove the beat. Keytruda remained the key growth engine, while the injectable version reportedly exceeded Wall Street’s sales forecast by more than $200 million. Strength in oncology and recently launched products supported the improved outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its 2026 revenue guidance to approximately $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion consensus estimate. The revision signals confidence in demand for its oncology portfolio and newer medicines. Merck hikes revenue outlook as new drug sales grow
• Neutral Sentiment: Management highlighted additional regulatory, clinical and pipeline milestones, including updates to its HIV program. These developments may support longer-term growth, but they do not materially change current-year earnings expectations. Merck Announces Second-Quarter 2026 Financial Results
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, far below the prior analyst consensus of $3.42. Acquisition-related charges from the Terns deal are weighing on reported profits, and the company’s quarterly loss compares with $2.13 EPS in the year-ago period. Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.